John Laurie
University Hospitals Sussex NHS Foundation Trust(GB)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Neutropenia and Cancer Infections, Protein Degradation and Inhibitors, Hemoglobinopathies and Related Disorders
Most-Cited Works
- → Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial(2023)129 cited
- → Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy(2023)61 cited
- → Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS(2024)28 cited
- パート1:エグゼクティブ・サマリー 心肺機能蘇生と救急心血管ケアに関する米国心臓病協会ガイドライン2010年版(2010)
- → Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service(2021)6 cited
- → Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service(2021)4 cited
- → Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial(2022)4 cited
- → Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy(2022)2 cited
- → Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study(2025)1 cited
- → Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations(2025)